Meeting
2015 Gastrointestinal Cancers Symposium
Efficacy and safety of regorafenib in Korean patients with advanced gastrointestinal stromal tumor after failure of imatinib and sunitinib: A multicenter study based on the management access program.
Authors
Myoung Kyun Son
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Myoung Kyun Son , Min-Hee Ryu , Joon Oh Park , Seock-Ah Im , Baek-Yeol Ryoo , Sook Ryun Park , Yoon-Koo Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 175)
DOI
10.1200/jco.2015.33.3_suppl.175
Abstract #
175
Poster Bd #
D23
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
First Author: Jian Li
Poster
2018 ASCO Annual Meeting
Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
First Author: Yoon-Koo Kang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.
First Author: Takahito Awatsu
Poster
2020 ASCO Virtual Scientific Program
Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.
First Author: Suzanne George